LVP and SVP formulation considerations MCQs With Answer
Formulating Large Volume Parenterals (LVPs) and Small Volume Parenterals (SVPs) demands a rigorous understanding of sterility assurance, endotoxin control, particulate limits, container–closure compatibility, and clinical tolerability. This MCQ set is designed for M. Pharm students to sharpen decision-making on key design choices such as terminal sterilization vs. aseptic processing, buffer and tonicity selection, material compatibility (glass/plastics), and preservative use. You will also encounter scenario-driven questions on IV emulsion quality metrics, lyophilization aids, endotoxin calculations, and prevention of precipitation in parenteral nutrition. Each question targets practical, regulation-aligned formulation decisions, grounding you in USP/Ph. Eur. expectations and cGMP realities. Use these MCQs to test depth, not just recall.
Q1. What is the most accepted volume-based classification distinguishing LVP from SVP?
- Products with fill volume ≥100 mL are LVP; ≤100 mL are SVP
- LVP is defined as >500 mL only
- SVP is defined as ≤10 mL only
- Classification is based on drug potency, not volume
Correct Answer: Products with fill volume ≥100 mL are LVP; ≤100 mL are SVP
Q2. Which statement on antimicrobial preservatives is most appropriate for parenterals?
- LVP must not contain bacteriostatic preservatives due to risk of toxicity
- LVP commonly include benzyl alcohol 0.9% for safety
- SVP single-dose containers must contain preservatives
- Preservatives are mandatory for all parenterals
Correct Answer: LVP must not contain bacteriostatic preservatives due to risk of toxicity
Q3. Regarding sterilization strategy for parenterals, which is preferred when feasible?
- Terminal moist-heat sterilization at 121 °C is preferred whenever product can withstand it
- Aseptic filtration is always preferred over terminal sterilization
- Dry heat sterilization is used for aqueous LVP solutions
- Gamma irradiation is routine for all SVPs
Correct Answer: Terminal moist-heat sterilization at 121 °C is preferred whenever product can withstand it
Q4. In aseptic processing of SVPs, which approach ensures microbial retention and verification?
- 0.22 µm sterilizing-grade filtration followed by filter integrity test (e.g., bubble point) is standard for aseptically filled SVPs
- 0.45 µm membrane ensures sterility for all parenterals
- Integrity testing is optional if process is validated
- 5.0 µm filter ensures depyrogenation
Correct Answer: 0.22 µm sterilizing-grade filtration followed by filter integrity test (e.g., bubble point) is standard for aseptically filled SVPs
Q5. Which statement best reflects the principle for calculating endotoxin limits for injections?
- Bacterial endotoxin limit is calculated as K/M, where K is 5 EU/kg for IV and 0.2 EU/kg for intrathecal
- Endotoxin limits are fixed at 0.25 EU/mL for all parenterals
- Endotoxin testing is not required for LVP
- K/M uses K = 50 EU/kg for IV
Correct Answer: Bacterial endotoxin limit is calculated as K/M, where K is 5 EU/kg for IV and 0.2 EU/kg for intrathecal
Q6. What is the USP <788> particulate matter limit for large-volume injections by light obscuration?
- For large-volume injections, NMT 25 particles ≥10 µm/mL and NMT 3 particles ≥25 µm/mL by light obscuration
- For large-volume injections, NMT 6000 particles ≥10 µm per container
- Limits are the same for LVP and SVP
- Only microscopic method applies to LVP
Correct Answer: For large-volume injections, NMT 25 particles ≥10 µm/mL and NMT 3 particles ≥25 µm/mL by light obscuration
Q7. What is the USP <788> limit for particulate matter in small-volume injections by light obscuration?
- For small-volume injections, NMT 6000 particles ≥10 µm/container and NMT 600 particles ≥25 µm/container by light obscuration
- For SVP, limits are per mL
- For SVP, NMT 25 particles ≥10 µm/mL
- Particulate testing is waived if solution is clear
Correct Answer: For small-volume injections, NMT 6000 particles ≥10 µm/container and NMT 600 particles ≥25 µm/container by light obscuration
Q8. Which statement best guides buffer selection for LVPs?
- Use minimal buffering capacity; prefer acetate/citrate over phosphate to reduce precipitation risk
- Strong phosphate buffers are preferred to maintain constant pH
- Borate buffer is ideal for all IV infusions
- LVP should not be buffered
Correct Answer: Use minimal buffering capacity; prefer acetate/citrate over phosphate to reduce precipitation risk
Q9. What is the desired tonicity range for peripheral IV LVPs?
- Target osmolality for peripheral IV LVP is approximately 275–310 mOsm/kg
- Hypertonic LVPs (>900 mOsm/kg) are suitable for peripheral veins
- Hypotonic LVPs (<150 mOsm/kg) are well tolerated
- Tonicity adjustment is unnecessary for parenterals
Correct Answer: Target osmolality for peripheral IV LVP is approximately 275–310 mOsm/kg
Q10. Which pH range is commonly targeted in LVPs to balance stability and tolerability?
- pH 4–8 is a common target for LVP to balance stability and minimize irritation
- pH 1–3 is acceptable for most IV LVPs without irritation
- All IV injections must be at physiological pH 7.40
- pH control is irrelevant for SVPs
Correct Answer: pH 4–8 is a common target for LVP to balance stability and minimize irritation
Q11. Which packaging selection is most appropriate based on formulation reactivity?
- Type II (treated soda-lime) glass is acceptable for acidic/neutral SVPs; Type I borosilicate is preferred for alkaline or sensitive products
- Type III glass is suitable for most aqueous injections
- Plastic bags are unacceptable for LVPs
- Type I borosilicate should never be used for SVPs
Correct Answer: Type II (treated soda-lime) glass is acceptable for acidic/neutral SVPs; Type I borosilicate is preferred for alkaline or sensitive products
Q12. Which statement on adsorption and infusion materials is correct?
- Drugs like nitroglycerin and diazepam adsorb to PVC; use glass or non-PVC polyolefin bags/tubing
- Adsorption is not a concern in LVPs
- PVC is universally compatible with all drugs
- Using surfactant eliminates adsorption concerns completely
Correct Answer: Drugs like nitroglycerin and diazepam adsorb to PVC; use glass or non-PVC polyolefin bags/tubing
Q13. What is the preservative consideration for neonatal parenterals?
- Benzyl alcohol should be avoided in neonatal parenterals due to toxicity (“gasping syndrome”)
- Phenol is safe in all neonatal SVPs
- Multidose SVPs are preferred in neonates for convenience
- Preservatives have no impact on neonatal safety
Correct Answer: Benzyl alcohol should be avoided in neonatal parenterals due to toxicity (“gasping syndrome”)
Q14. Which is the correct statement about multidose parenteral container size?
- Maximum volume for a multidose parenteral container is generally 30 mL
- Multidose LVPs are 250–1000 mL
- Multidose SVPs must be at least 50 mL
- There is no limit on multidose container size
Correct Answer: Maximum volume for a multidose parenteral container is generally 30 mL
Q15. For minimizing oxidation in parenterals, which practice is preferred, especially for LVPs?
- Antioxidants and chelators are generally avoided in LVPs; oxygen control (e.g., nitrogen overlay) is preferred
- High levels of sulfites are routinely added to LVPs
- Antioxidants are mandatory in all SVPs
- Removing headspace oxygen has no effect on oxidation
Correct Answer: Antioxidants and chelators are generally avoided in LVPs; oxygen control (e.g., nitrogen overlay) is preferred
Q16. In SVP lyophilization, which statement is accurate regarding formulation aids?
- Cryo/lyoprotectants such as sucrose, trehalose, or mannitol are used in SVP lyophilization to stabilize proteins and form elegant cakes
- Lyophilization is unsuitable for SVPs
- Sodium chloride is the preferred bulking agent for lyophilized biologics
- Lyophilized SVPs are terminally sterilized by moist heat after drying
Correct Answer: Cryo/lyoprotectants such as sucrose, trehalose, or mannitol are used in SVP lyophilization to stabilize proteins and form elegant cakes
Q17. Which quality criteria apply to IV lipid emulsions per USP <729>?
- IV lipid emulsions must have mean droplet diameter ≤500 nm and PFAT5 ≤0.05% per USP <729>
- Emulsion droplet size may exceed 5 µm without risk
- PFAT5 measures particles larger than 50 µm
- Emulsions need not meet any globule size tests
Correct Answer: IV lipid emulsions must have mean droplet diameter ≤500 nm and PFAT5 ≤0.05% per USP <729>
Q18. Which statement best reflects current expectations for Container-Closure Integrity Testing (CCIT)?
- Deterministic methods (e.g., vacuum decay, helium leak) are preferred for container-closure integrity over dye ingress alone
- CCIT is unnecessary if sterility test passes
- Only dye ingress is accepted by regulators
- Visual inspection replaces CCIT for SVPs
Correct Answer: Deterministic methods (e.g., vacuum decay, helium leak) are preferred for container-closure integrity over dye ingress alone
Q19. Which is true regarding Water for Injection (WFI) used in parenteral manufacture?
- Bulk Water for Injection is not sterile but must meet endotoxin limit ≤0.25 EU/mL and be produced and used under controlled conditions
- Bulk WFI is sterile by definition
- Potable water can replace WFI for LVP compounding if filtered
- WFI must always be stored at room temperature to avoid leachables
Correct Answer: Bulk Water for Injection is not sterile but must meet endotoxin limit ≤0.25 EU/mL and be produced and used under controlled conditions
Q20. How can calcium phosphate precipitation be minimized in parenteral nutrition (PN) LVPs?
- Use calcium gluconate, avoid high phosphate and prefer acetate buffer; order of mixing matters to reduce calcium phosphate precipitation
- Use calcium chloride and phosphate buffers early to maximize solubility
- High pH promotes calcium phosphate solubility in PN
- Buffer choice has no effect on precipitation
Correct Answer: Use calcium gluconate, avoid high phosphate and prefer acetate buffer; order of mixing matters to reduce calcium phosphate precipitation
